Are any of you participating in a phase 1 or phase 2 trial studying an alternative to the radioligand Pluvicto?
I ask because I was one business day away from getting my first dose of Pluvicto when new patients were turned away due to quality control problems. Based on part of the Novartis news release late last week (shown below) new patients like me may be hosed for the rest of 2023.
Thanks.
+++++++++++++++
In the letter, the company said that it currently only manufactures Pluvicto in Italy in "small batches," and is awaiting FDA approval on a new manufacturing site. That approval was expected to come in four to six months, Novartis said. Novartis said it will not take any new orders until there is "clarity on the FDA's approval" of its new manufacturing facility.